FDA Approves Nivolumab for Certain Patients With Previously Treated Small Cell Lung Cancer

August 17, 2018 – Today, nivolumab received approval from the U.S. Food and Drug Administration (FDA) for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. Approval for this indication has been granted under accelerated approval based on overall response rate and duration of response. This approval for nivolumab had been granted Priority Review from the … (leggi tutto)